A case of Ménétriere´s disease treated with the monoclonal antibody cetuximab

Clin J Gastroenterol. 2019 Dec;12(6):562-565. doi: 10.1007/s12328-019-00994-8. Epub 2019 May 23.

Abstract

Ménétriere´s disease is a rare disorder of the body and fundus of the stomach, characterized by a massive proliferation of the foveolar cells and subsequent excess mucous secretion. This results in hypoproteinemia due to loss of serum proteins across the gastric mucosa. The cause of Ménétriere´s disease is unknown, and due to the irreversible and premalignant character of the disorder, the patients affected have been subdued to gastrectomy as the only curable treatment. Epidermial growth factor (EGF) has been implicated in the pathogenesis, a finding that makes the disorder receptive to monoclonal antibody treatment against the EGF receptor. In this case report, we present a 41-year-old woman referred to our emergency department due to dizziness, nausea, and vomiting. A thorough medical investigation, combining clinical history, laboratory investigations, an upper endoscopy with full-thickness snare biopsies, and a CT scan confirmed Ménétriere´s disease, and she was successfully treated with the monoclonal antibody cetuximab.

Keywords: Cetuximab; Epidermial growth factor receptor; Hypoproteinemic hypertrophic gastropathy; Ménétriere´s disease.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Cetuximab / administration & dosage*
  • Drug Administration Schedule
  • Female
  • Gastritis, Hypertrophic / drug therapy*
  • Gastrointestinal Agents / administration & dosage*
  • Humans
  • Infusions, Intravenous
  • Off-Label Use
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Gastrointestinal Agents
  • Cetuximab